5-Year Follow-Up Of The Safety, Tolerability And Efficacy Of Subcutaneous Trastuzumab For The Adjuvant Treatment Of Her2-Positive Early Breast Cancer. Results From The Safeher Phase Iii Trial
BREAST(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要